RNAi: A potential new class of therapeutic for human genetic disease

Human Genetics

Volumn 130, Issue 5, 2011, Pages 583-605

  Seyhan, Attila A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; COMPLEMENTARY RNA; DOUBLE STRANDED RNA; LENTIVIRUS VECTOR; LIPOPLEX; MICRORNA; NANOPARTICLE; PARVOVIRUS VECTOR; PIWI INTERACTING RNA; RETROVIRUS VECTOR; RIBOZYME; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOSOMAL DOMINANT DISORDER; CHRONIC MYELOID LEUKEMIA; CONGENITAL MYASTHENIC SYNDROME; CONGENITAL PACHYONYCHIA; CONJUGATE; DRUG POTENCY; DRUG SPECIFICITY; DUCHENNE MUSCULAR DYSTROPHY; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION REGULATION; GENETIC DISORDER; HEPATITIS; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; KIDNEY INJURY; MUSCULAR DYSTROPHY; NEOPLASM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; RNA INTERFERENCE; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; SPINOCEREBELLAR DEGENERATION; SPLICING DEFECT; TUMOR CELL;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA, SICKLE CELL; ANIMALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENES, DOMINANT; GENETIC DISEASES, INBORN; HUMANS; HUNTINGTON DISEASE; MICE; MOLECULAR TARGETED THERAPY; MUSCULAR DYSTROPHIES; NEOPLASMS; PARKINSON DISEASE; POINT MUTATION; RATS; RNA INTERFERENCE; SPINOCEREBELLAR ATAXIAS;

EID: 80054741160     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-011-0995-8     Document Type: Review

References (217)

1. L Aagaard JJ Rossi 2007 RNAi therapeutics: principles, prospects and challenges Adv Drug Deliv Rev 59 2-3 75 86 17449137 1:CAS:528: DC%2BD2sXlvVOhtLw%3D 10.1016/j.addr.2007.03.005 (Pubitemid 46770900)
2. A Abdelgany M Wood, et al. 2003 Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference Hum Mol Genet 12 20 2637 2644 12928480 1:CAS:528:DC%2BD3sXot1Cqtrc%3D 10.1093/hmg/ddg280 (Pubitemid 37304686)
3. A Abeliovich Y Schmitz, et al. 2000 Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 1 239 252 10707987 1:CAS:528:DC%2BD3cXhtVWrt74%3D 10.1016/S0896-6273(00)80886-7 (Pubitemid 30316525)
4. S Agrawal ER Kandimalla 2004 Role of Toll-like receptors in antisense and siRNA [corrected] Nat Biotechnol 22 12 1533 1537 15583662 1:CAS:528: DC%2BD2cXhtVCku77N 10.1038/nbt1042 (Pubitemid 40039455)
5. I Alevizos GG Illei 2010 MicroRNAs as biomarkers in rheumatic diseases Nat Rev Rheumatol 6 7 391 398 20517293 1:CAS:528:DC%2BC3cXotlSnu7s%3D 10.1038/nrrheum.2010.81
6. I Alevizos GG Illei 2010 MicroRNAs in Sjogren's syndrome as a prototypic autoimmune disease Autoimmun Rev 9 9 618 621 20457282 1:CAS:528: DC%2BC3cXpsVGgsLo%3D 10.1016/j.autrev.2010.05.009
7. M Amarzguioui T Holen, et al. 2003 Tolerance for mutations and chemical modifications in a siRNA Nucleic Acids Res 31 2 589 595 12527766 1:CAS:528:DC%2BD3sXitlCgurk%3D 10.1093/nar/gkg147 (Pubitemid 36175948)
8. V Ambros 2004 The functions of animal microRNAs Nature 431 7006 350 355 15372042 1:CAS:528:DC%2BD2cXnsFaiu7g%3D 10.1038/nature02871 (Pubitemid 39265675)
9. M Ameyar-Zazoua V Guasconi, et al. 2005 siRNA as a route to new cancer therapies Expert Opin Biol Ther 5 2 221 224 15757383 1:CAS:528: DC%2BD2MXhsFSnu74%3D 10.1517/14712598.5.2.221 (Pubitemid 40388851)
10. P Arbuthnot 2010 Harnessing RNA interference for the treatment of viral infections Drug News Perspect 23 6 341 350 20697601 1:CAS:528:DC%2BC3cXht1KrurjI
11. S Barik 2004 Development of gene-specific double-stranded RNA drugs Ann Med 36 7 540 551 15513304 1:CAS:528:DC%2BD2cXos1GhtL4%3D 10.1080/ 07853890410018817 (Pubitemid 39490963)
12. DP Bartel 2004 MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2 281 297 14744438 1:CAS:528:DC%2BD2cXhtVals7o%3D 10.1016/S0092- 8674(04)00045-5 (Pubitemid 38167318)
13. DP Bartel 2009 MicroRNAs: target recognition and regulatory functions Cell 136 2 215 233 19167326 1:CAS:528:DC%2BD1MXhs1Kiuro%3D 10.1016/j.cell.2009. 01.002
14. DJ Begley 2004 Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol Ther 104 1 29 45 15500907 1:CAS:528:DC%2BD2cXovVKqsrc%3D 10.1016/j.pharmthera.2004.08.001 (Pubitemid 39410561)
15. MA Behlke 2008 Chemical modification of siRNAs for in vivo use Oligonucleotides 18 4 305 319 19025401 1:CAS:528:DC%2BD1cXhsVGhu77N 10.1089/oli.2008.0164 (Pubitemid 352791344)
16. A Berns 2010 Cancer: the blind spot of p53 Nature 468 7323 519 520 21107421 1:CAS:528:DC%2BC3cXhsVOrsLnM 10.1038/468519a
17. CI Berul CT Maguire, et al. 1999 DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model J Clin Invest 103 4 R1 R7 10021468 1:CAS:528:DyaK1MXhslWqsbw%3D 10.1172/JCI5346
18. A Birmingham EM Anderson, et al. 2006 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets Nat Methods 3 3 199 204 16489337 1:CAS:528:DC%2BD28XhsFOru7Y%3D 10.1038/nmeth854
19. RJ Boado Y Zhang, et al. 2007 Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation Bioconjug Chem 18 2 447 455 17315944 1:CAS:528: DC%2BD2sXhvFKqs7g%3D 10.1021/bc060349x (Pubitemid 46493516)
20. D Boison 2010 Inhibitory RNA in epilepsy: research tools and therapeutic perspectives Epilepsia 51 9 1659 1668 20633035 1:CAS:528:DC%2BC3cXht1eqtr3I 10.1111/j.1528-1167.2010.02672.x
21. RL Boudreau JL McBride, et al. 2009 Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice Mol Ther 17 6 1053 1063 19240687 1:CAS:528: DC%2BD1MXit1agtb4%3D 10.1038/mt.2009.17
22. TR Brummelkamp R Bernards, et al. 2002 Stable suppression of tumorigenicity by virus-mediated RNA interference Cancer Cell 2 3 243 247 12242156 1:CAS:528:DC%2BD38Xnt1yhur8%3D 10.1016/S1535-6108(02)00122-8 (Pubitemid 41043979)
23. D Bumcrot M Manoharan, et al. 2006 RNAi therapeutics: a potential new class of pharmaceutical drugs Nat Chem Biol 2 12 711 719 17108989 1:CAS:528:DC%2BD28Xht1SrtLfO 10.1038/nchembio839 (Pubitemid 44764213)
24. EN Burright HB Clark, et al. 1995 SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat Cell 82 6 937 948 7553854 1:CAS:528:DyaK2MXotlClt70%3D 10.1016/0092-8674(95)90273-2
25. A Care D Catalucci, et al. 2007 MicroRNA-133 controls cardiac hypertrophy Nat Med 13 5 613 618 17468766 1:CAS:528:DC%2BD2sXkvVOgsrw%3D 10.1038/nm1582 (Pubitemid 46828487)
26. D Castanotto JJ Rossi 2009 The promises and pitfalls of RNA-interference-based therapeutics Nature 457 7228 426 433 19158789 1:CAS:528:DC%2BD1MXotlOgsA%3D%3D 10.1038/nature07758
27. CK Cemal CJ Carroll, et al. 2002 YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit Hum Mol Genet 11 9 1075 1094 11978767 1:CAS:528: DC%2BD38XjvFSntbw%3D 10.1093/hmg/11.9.1075 (Pubitemid 34521089)
28. TC Chang EA Wentzel, et al. 2007 Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis Mol Cell 26 5 745 752 17540599 1:CAS:528:DC%2BD2sXnt1Cquro%3D 10.1016/j.molcel.2007.05.010 (Pubitemid 46856245)
29. EJ Chapman JC Carrington 2007 Specialization and evolution of endogenous small RNA pathways Nat Rev Genet 8 11 884 896 17943195 1:CAS:528: DC%2BD2sXhtFOksL7K 10.1038/nrg2179 (Pubitemid 47609087)
30. S Charache GJ Dover, et al. 1987 Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia Blood 69 1 109 116 2431728 1:STN:280:DyaL2s%2Fns12gtw%3D%3D (Pubitemid 17007083)
31. J Chen NR Wall, et al. 2004 Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin J Clin Invest 113 12 1784 1791 15199413 1:CAS:528:DC%2BD2cXkvFyjsbg%3D (Pubitemid 39071670)
32. HY Cheng JW Papp, et al. 2007 microRNA modulation of circadian-clock period and entrainment Neuron 54 5 813 829 17553428 1:CAS:528: DC%2BD2sXntVOjtrg%3D 10.1016/j.neuron.2007.05.017 (Pubitemid 46843524)
33. DH Cho SJ Tapscott 2007 Myotonic dystrophy: emerging mechanisms for DM1 and DM2 Biochim Biophys Acta 1772 2 195 204 16876389 1:CAS:528: DC%2BD2sXpvVymtw%3D%3D (Pubitemid 46123909)
34. TC Chu KY Twu, et al. 2006 Aptamer mediated siRNA delivery Nucleic Acids Res 34 10 e73 16740739 10.1093/nar/gkl388 1:CAS:528:DC%2BD28XnsFKrurk%3D (Pubitemid 44540445)
35. JH Chua A Armugam, et al. 2009 MicroRNAs: biogenesis, function and applications Curr Opin Mol Ther 11 2 189 199 19330724 1:CAS:528: DC%2BC3cXnt1Kgurc%3D
36. R Croxen C Hatton, et al. 2002 Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes Neurology 59 2 162 168 12141316 1:CAS:528:DC%2BD38Xmt1Sisbo%3D (Pubitemid 34779171)
37. BR Cullen 2006 Induction of stable RNA interference in mammalian cells Gene Ther 13 6 503 508 16195700 1:CAS:528:DC%2BD28XitVGnurk%3D 10.1038/sj.gt.3302656
38. C Damm-Welk U Fuchs, et al. 2003 Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference Semin Cancer Biol 13 4 283 292 14563123 1:CAS:528:DC%2BD3sXntFyku7w%3D 10.1016/S1044-579X(03)00042-7 (Pubitemid 38160920)
39. BL Davidson RL Boudreau 2007 RNA interference: a tool for querying nervous system function and an emerging therapy Neuron 53 6 781 788 17359914 1:CAS:528:DC%2BD2sXktFCmtL4%3D 10.1016/j.neuron.2007.02.020 (Pubitemid 46367555)
40. BL Davidson XO Breakefield 2003 Viral vectors for gene delivery to the nervous system Nat Rev Neurosci 4 5 353 364 12728263 1:CAS:528: DC%2BD3sXjtlalsbo%3D 10.1038/nrn1104 (Pubitemid 37280174)
41. BL Davidson HL Paulson 2004 Molecular medicine for the brain: silencing of disease genes with RNA interference Lancet Neurol 3 3 145 149 14980529 1:CAS:528:DC%2BD2cXjtVCqtLs%3D 10.1016/S1474-4422(04)00678-7 (Pubitemid 38229948)
42. ME Davis JE Zuckerman, et al. 2010 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 7291 1067 1070 20305636 1:CAS:528:DC%2BC3cXjs1ehur8%3D 10.1038/nature08956
43. A de Fougerolles HP Vornlocher, et al. 2007 Interfering with disease: a progress report on siRNA-based therapeutics Nat Rev Drug Discov 6 6 443 453 17541417 10.1038/nrd2310 1:CAS:528:DC%2BD2sXmtVSmtbc%3D (Pubitemid 47064567)
44. EM Denovan-Wright BL Davidson 2006 RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases Gene Ther 13 6 525 531 16237462 1:CAS:528:DC%2BD28XitVGnurY%3D 10.1038/sj.gt.3302664
45. JP DeVincenzo 2009 Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials Early Hum Dev 85 10 Suppl S31 S35 19833462 1:CAS:528:DC%2BD1MXhtlGiu7jJ 10.1016/j.earlhumdev.2009.08.013
46. M DiFiglia M Sena-Esteves, et al. 2007 Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits Proc Natl Acad Sci USA 104 43 17204 17209 17940007 1:CAS:528:DC%2BD2sXht1Kit7rK 10.1073/pnas.0708285104 (Pubitemid 350211015)
47. CP Dillon P Sandy, et al. 2005 Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes Annu Rev Physiol 67 147 173 15709955 1:CAS:528:DC%2BD2MXjsFelu7o%3D 10.1146/annurev.physiol.67. 040403.130716 (Pubitemid 40404488)
48. H Ding DS Schwarz, et al. 2003 Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis Aging Cell 2 4 209 217 12934714 1:CAS:528:DC%2BD3sXmt1CrsbY%3D 10.1046/j.1474-9728.2003.00054.x
49. JG Doench CP Petersen, et al. 2003 siRNAs can function as miRNAs Genes Dev 17 4 438 442 12600936 1:CAS:528:DC%2BD3sXhslCqtbo%3D 10.1101/gad.1064703 (Pubitemid 36258757)
50. L Dore-Savard G Roussy, et al. 2008 Central delivery of Dicer-substrate siRNA: a direct application for pain research Mol Ther 16 7 1331 1339 18523447 1:CAS:528:DC%2BD1cXns1ehsrY%3D 10.1038/mt.2008.98 (Pubitemid 351866066)
51. V Drouet V Perrin, et al. 2009 Sustained effects of nonallele-specific Huntingtin silencing Ann Neurol 65 3 276 285 19334076 1:CAS:528: DC%2BD1MXltVOkt70%3D 10.1002/ana.21569
52. DM Dykxhoorn CD Novina, et al. 2003 Killing the messenger: short RNAs that silence gene expression Nat Rev Mol Cell Biol 4 6 457 467 12778125 1:CAS:528:DC%2BD3sXktFOns74%3D 10.1038/nrm1129 (Pubitemid 36648591)
53. DM Dykxhoorn LD Schlehuber, et al. 2006 Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism Proc Natl Acad Sci USA 103 15 5953 5958 16585504 1:CAS:528:DC%2BD28XktFaitLc%3D 10.1073/pnas.0601309103
54. SM Elbashir W Lendeckel, et al. 2001 RNA interference is mediated by 21- and 22-nucleotide RNAs Genes Dev 15 2 188 200 11157775 1:CAS:528: DC%2BD3MXhvVOjtbg%3D 10.1101/gad.862301 (Pubitemid 32107664)
55. SM Elbashir J Martinez, et al. 2001 Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate EMBO J 20 23 6877 6888 11726523 1:CAS:528:DC%2BD3MXptVaqurw%3D 10.1093/emboj/20.23.6877 (Pubitemid 33134217)
56. JL Eriksen Z Wszolek, et al. 2005 Molecular pathogenesis of Parkinson disease Arch Neurol 62 3 353 357 15767499 10.1001/archneur.62.3.353 (Pubitemid 40349469)
57. AE Erson EM Petty 2008 MicroRNAs in development and disease Clin Genet 74 4 296 306 18713256 1:CAS:528:DC%2BD1cXhsVyms7zM 10.1111/j.1399-0004.2008.01076. x
58. DM Feldser KK Kostova, et al. 2010 Stage-specific sensitivity to p53 restoration during lung cancer progression Nature 468 7323 572 575 21107428 1:CAS:528:DC%2BC3cXhsVOrsbnK 10.1038/nature09535
59. KM Flanigan CM Coffeen, et al. 2001 Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy Neuromuscul Disord 11 6-7 525 529 11525880 1:STN:280:DC%2BD3MvotlWhtA%3D%3D 10.1016/S0960-8966(01)00201-2 (Pubitemid 32761794)
60. KD Foust E Nurre, et al. 2009 Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes Nat Biotechnol 27 1 59 65 19098898 1:CAS:528:DC%2BD1cXhsFajtbbJ 10.1038/nbt.1515
61. NR Franich HL Fitzsimons, et al. 2008 AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease Mol Ther 16 5 947 956 18388917 1:CAS:528: DC%2BD1cXltFehsLY%3D 10.1038/mt.2008.50 (Pubitemid 351587106)
62. AL Gartel ES Kandel 2006 RNA interference in cancer Biomol Eng 23 1 17 34 16466964 1:CAS:528:DC%2BD28XhsFOis7w%3D 10.1016/j.bioeng.2006.01.002 (Pubitemid 43243836)
63. Gaur RK (2006) RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases. Biotechniques 40:S15-S22. doi: 10.2144/000112165
64. M Ghildiyal PD Zamore 2009 Small silencing RNAs: an expanding universe Nat Rev Genet 10 2 94 108 19148191 1:CAS:528:DC%2BD1MXlvFChtA%3D%3D 10.1038/nrg2504
65. CS Gondi SS Lakka, et al. 2004 RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas Oncogene 23 52 8486 8496 15378018 1:CAS:528:DC%2BD2cXpt1OmsLc%3D 10.1038/sj.onc.1207879 (Pubitemid 39540799)
66. P Gonzalez-Alegre HL Paulson, et al. 2007 Technology insight: therapeutic RNA interference-how far from the neurology clinic? Nat Clin Pract Neurol 3 7 394 404 17611488 1:CAS:528:DC%2BD2sXnt1ensrc%3D 10.1038/ncpneuro0551 (Pubitemid 47040329)
67. SJ Gray BL Blake, et al. 2010 Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB) Mol Ther 18 3 570 578 20040913 1:CAS:528: DC%2BD1MXhs1WntrrN 10.1038/mt.2009.292
68. MA Graziewicz TK Tarrant, et al. 2008 An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models Mol Ther 16 7 1316 1322 18461057 1:CAS:528: DC%2BD1cXns1eiu7c%3D 10.1038/mt.2008.85 (Pubitemid 351866064)
69. RI Gregory KP Yan, et al. 2004 The Microprocessor complex mediates the genesis of microRNAs Nature 432 7014 235 240 15531877 1:CAS:528: DC%2BD2cXpsF2gt7g%3D 10.1038/nature03120 (Pubitemid 39545855)
70. Grimm D, Kay MA (2007) RNAi and gene therapy: a mutual attraction. Hematol Am Soc Hematol Educ Program 473-481
71. D Grimm KL Streetz, et al. 2006 Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways Nature 441 7092 537 541 16724069 1:CAS:528:DC%2BD28XkvVyku7g%3D 10.1038/nature04791 (Pubitemid 44050158)
72. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX et al (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264(5166):1772-1775 (Pubitemid 24227760)
73. S Hacein-Bey-Abina J Hauer, et al. 2010 Efficacy of gene therapy for X-linked severe combined immunodeficiency N Engl J Med 363 4 355 364 20660403 1:CAS:528:DC%2BC3cXptFSlu7s%3D 10.1056/NEJMoa1000164
74. AJ Hamilton DC Baulcombe 1999 A species of small antisense RNA in posttranscriptional gene silencing in plants Science 286 5441 950 952 10542148 1:CAS:528:DyaK1MXntFaktbY%3D 10.1126/science.286.5441.950
75. SM Hammond E Bernstein, et al. 2000 An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells Nature 404 6775 293 296 10749213 1:CAS:528:DC%2BD3cXit1agtrw%3D 10.1038/35005107 (Pubitemid 30163547)
76. J Harborth SM Elbashir, et al. 2001 Identification of essential genes in cultured mammalian cells using small interfering RNAs J Cell Sci 114 Pt 24 4557 4565 11792820 1:CAS:528:DC%2BD38XnvFKksQ%3D%3D (Pubitemid 34086890)
77. TC Harding AS Lalani, et al. 2006 AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma Mol Ther 13 5 956 966 16580881 1:CAS:528:DC%2BD28XjvV2qs7Y%3D 10.1016/j.ymthe.2006.02. 004
78. J Hardy DJ Selkoe 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 5580 353 356 12130773 1:CAS:528:DC%2BD38Xls1Cju7s%3D 10.1126/science.1072994 (Pubitemid 34790756)
79. PS Harper 1989 Postoperative complications in myotonic dystrophy Lancet 2 8674 1269 2573772 1:STN:280:DyaK3c%2FmsFyjtg%3D%3D 10.1016/S0140-6736(89)91867- 9 (Pubitemid 19284139)
80. SQ Harper 2009 Progress and challenges in RNA interference therapy for Huntington disease Arch Neurol 66 8 933 938 19667213 10.1001/archneurol.2009.180
81. SQ Harper PD Staber, et al. 2005 RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc Natl Acad Sci USA 102 16 5820 5825 15811941 1:CAS:528:DC%2BD2MXjslaktbo%3D 10.1073/pnas.0501507102 (Pubitemid 40559643)
82. L He JM Thomson, et al. 2005 A microRNA polycistron as a potential human oncogene Nature 435 7043 828 833 15944707 1:CAS:528:DC%2BD2MXkvVGgs70%3D 10.1038/nature03552 (Pubitemid 40839734)
83. T Holen M Amarzguioui, et al. 2002 Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor Nucleic Acids Res 30 8 1757 1766 11937629 1:CAS:528:DC%2BD38Xjt1Ghsbk%3D 10.1093/nar/30.8.1757 (Pubitemid 34679753)
84. V Hornung M Guenthner-Biller, et al. 2005 Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7 Nat Med 11 3 263 270 15723075 1:CAS:528:DC%2BD2MXhvVSru7o%3D 10.1038/nm1191 (Pubitemid 40460553)
85. WA Horton 2005 Therapeutic RNAi for genetic skeletal disease? Growth Genet Horm 21 1 11 12
86. B Huang J Schiefer, et al. 2007 High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo Hum Gene Ther 18 4 303 311 17472569 1:CAS:528:DC%2BD2sXkvVWqsLc%3D 10.1089/hum.2006.160 (Pubitemid 46709342)
87. S Hu-Lieskovan JD Heidel, et al. 2005 Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res 65 19 8984 8992 16204072 1:CAS:528:DC%2BD2MXhtVKiu7rI 10.1158/0008-5472.CAN-05-0565 (Pubitemid 41377390)
88. I. H. G. S. Consortium 2001 Initial sequencing and analysis of the human genome Nature 409 6822 860 921 10.1038/35057062 (Pubitemid 32165345)
89. H Ilves RL Kaspar, et al. 2006 Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice Ann N Y Acad Sci 1082 52 55 17145925 1:CAS:528:DC%2BD2sXmvFOgsA%3D%3D 10.1196/annals.1348. 060 (Pubitemid 44955449)
90. AL Jackson SR Bartz, et al. 2003 Expression profiling reveals off-target gene regulation by RNAi Nat Biotechnol 21 6 635 637 12754523 1:CAS:528:DC%2BD3sXktFSlu7c%3D 10.1038/nbt831 (Pubitemid 36638089)
91. AL Jackson J Burchard, et al. 2006 Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing RNA 12 7 1197 1205 16682562 1:CAS:528:DC%2BD28Xms1Cquro%3D 10.1261/rna.30706 (Pubitemid 43990545)
92. AL Jackson J Burchard, et al. 2006 Widespread siRNA "off- target" transcript silencing mediated by seed region sequence complementarity RNA 12 7 1179 1187 16682560 1:CAS:528:DC%2BD28Xms1Cqurw%3D 10.1261/rna.25706 (Pubitemid 43990543)
93. AD Judge V Sood, et al. 2005 Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA Nat Biotechnol 23 4 457 462 15778705 1:CAS:528:DC%2BD2MXivFOhtLk%3D 10.1038/nbt1081 (Pubitemid 41724921)
94. RL Juliano 2005 Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA Curr Opin Mol Ther 7 2 132 136 15844620 1:CAS:528: DC%2BD2MXjvFSgtbY%3D (Pubitemid 40514682)
95. MM Juntilla VD Patil, et al. 2010 AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species Blood 115 20 4030 4038 20354168 1:CAS:528:DC%2BC3cXnt1Ggsb4%3D
96. S Khaliq SA Khaliq, et al. 2010 RNAi as a new therapeutic strategy against HCV Biotechnol Adv 28 1 27 34 19729057 1:CAS:528:DC%2BD1MXhsFGrtL3E 10.1016/j.biotechadv.2009.08.004
97. A Khvorova A Reynolds, et al. 2003 Functional siRNAs and miRNAs exhibit strand bias Cell 115 2 209 216 14567918 1:CAS:528:DC%2BD3sXosFCqsLs%3D 10.1016/S0092-8674(03)00801-8 (Pubitemid 37329584)
98. D Kim J Rossi 2008 RNAi mechanisms and applications Biotechniques 44 5 613 616 18474035 1:CAS:528:DC%2BD1cXltlWru7Y%3D 10.2144/000112792 (Pubitemid 351656279)
99. Kim DH, Rossi JJ (2009) Overview of gene silencing by RNA interference, Chap 16. Curr Protoc Nucleic Acid Chem (Unit 16 11)
100. DH Kim MA Behlke, et al. 2005 Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy Nat Biotechnol 23 2 222 226 15619617 1:CAS:528:DC%2BD2MXhtVGnu74%3D 10.1038/nbt1051 (Pubitemid 40255333)
101. DH Kim LM Villeneuve, et al. 2006 Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells Nat Struct Mol Biol 13 9 793 797 16936726 1:CAS:528:DC%2BD28XptFWiuro%3D 10.1038/nsmb1142 (Pubitemid 44338773)
102. N Kock R Kasmieh, et al. 2007 Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL Neoplasia 9 5 435 442 17534449 1:CAS:528:DC%2BD2sXms1Krtr0%3D 10.1593/neo.07223 (Pubitemid 46799987)
103. M Koldehoff NK Steckel, et al. 2007 Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia Clin Exp Med 7 2 47 55 17609876 1:CAS:528:DC%2BD2sXnt1Kit74%3D 10.1007/s10238-007-0125-z (Pubitemid 47036743)
104. R Kole M Vacek, et al. 2004 Modification of alternative splicing by antisense therapeutics Oligonucleotides 14 1 65 74 15104897 1:CAS:528: DC%2BD2cXjtV2mtbw%3D 10.1089/154545704322988067 (Pubitemid 38524636)
105. T Komiya Y Park, et al. 2006 Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation Oncogene 25 45 6128 6132 16652146 1:CAS:528:DC%2BD28XhtVGhu7fF 10.1038/sj.onc.1209627 (Pubitemid 44562411)
106. P Kumar HS Ban, et al. 2008 T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 134 4 577 586 18691745 1:CAS:528:DC%2BD1cXhtVGqtrnJ 10.1016/j.cell.2008.06.034
107. M Lagos-Quintana R Rauhut, et al. 2001 Identification of novel genes coding for small expressed RNAs Science 294 5543 853 858 11679670 1:CAS:528:DC%2BD3MXotVChtb8%3D 10.1126/science.1064921 (Pubitemid 33032103)
108. M Lagos-Quintana R Rauhut, et al. 2002 Identification of tissue-specific microRNAs from mouse Curr Biol 12 9 735 739 12007417 1:CAS:528: DC%2BD38XjsFygtb4%3D 10.1016/S0960-9822(02)00809-6 (Pubitemid 34455427)
109. CN Landen Jr A Chavez-Reyes, et al. 2005 Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res 65 15 6910 6918 16061675 1:CAS:528:DC%2BD2MXmvFSlur0%3D 10.1158/0008-5472.CAN-05-0530 (Pubitemid 41060730)
110. MA Langlois C Boniface, et al. 2005 Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells J Biol Chem 280 17 16949 16954 15722335 1:CAS:528:DC%2BD2MXjsFOgtr8%3D 10.1074/jbc. M501591200 (Pubitemid 41389155)
111. SR Larsen JE Rasko 2005 Lymphoproliferative disorders: prospects for gene therapy Pathology 37 6 523 533 16373231 1:CAS:528:DC%2BD2MXhtlCntbbI 10.1080/00313020500402276 (Pubitemid 43030874)
112. SA Leachman RP Hickerson, et al. 2008 Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita J Dermatol Sci 51 3 151 157 18495438 1:CAS:528:DC%2BD1cXpsVCrsLg%3D 10.1016/j.jdermsci.2008.04.003
113. SA Leachman RP Hickerson, et al. 2010 First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder Mol Ther 18 2 442 446 19935778 1:CAS:528:DC%2BD1MXhsVGqs7bK 10.1038/mt.2009.273
114. RC Lee RL Feinbaum, et al. 1993 The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 75 5 843 854 8252621 1:CAS:528:DyaK2cXpslGqtA%3D%3D 10.1016/0092-8674(93)90529-Y (Pubitemid 24014542)
115. HC Lee MK Patel, et al. 2003 Abnormal Na channel gating in murine cardiac myocytes deficient in myotonic dystrophy protein kinase Physiol Genomics 12 2 147 157 12454205 1:CAS:528:DC%2BD3sXhtl2rur4%3D (Pubitemid 37139694)
116. BP Lewis CB Burge, et al. 2005 Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 120 1 15 20 15652477 1:CAS:528:DC%2BD2MXot1ChsA%3D%3D 10.1016/j.cell.2004.12.035 (Pubitemid 40094598)
117. M Li H Li, et al. 2006 RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy Ann N Y Acad Sci 1082 172 179 17145937 1:CAS:528:DC%2BD2sXmvFOntg%3D%3D 10.1196/annals.1348. 006 (Pubitemid 44955461)
118. QJ Li J Chau, et al. 2007 miR-181a is an intrinsic modulator of T cell sensitivity and selection Cell 129 1 147 161 17382377 1:CAS:528: DC%2BD2sXkvVeltLc%3D 10.1016/j.cell.2007.03.008 (Pubitemid 46507589)
119. CH Lin S Tallaksen-Greene, et al. 2001 Neurological abnormalities in a knock-in mouse model of Huntington's disease Hum Mol Genet 10 2 137 144 11152661 1:CAS:528:DC%2BD3MXns1KjtQ%3D%3D 10.1093/hmg/10.2.137 (Pubitemid 32098123)
120. X Lin X Ruan, et al. 2005 siRNA-mediated off-target gene silencing triggered by a 7 nt complementation Nucleic Acids Res 33 14 4527 4535 16091630 1:CAS:528:DC%2BD2MXovVKqt7s%3D 10.1093/nar/gki762 (Pubitemid 41222567)
121. P Lingor M Bahr 2007 Targeting neurological disease with RNAi Mol Biosyst 3 11 773 780 17940660 1:CAS:528:DC%2BD2sXhtFKlsLbP 10.1039/b701169e (Pubitemid 47587187)
122. Lovett-Racke, AE (2009). Therapeutic potential of small interfering RNA for brain diseases. Therapeutic Ribonucleic Acids in Brain Tumors. Springer-Verlag, Berlin, pp 275-295
123. J Lu G Getz, et al. 2005 MicroRNA expression profiles classify human cancers Nature 435 7043 834 838 15944708 1:CAS:528:DC%2BD2MXkvVGgsLc%3D 10.1038/nature03702 (Pubitemid 40839735)
124. Y Machida T Okada, et al. 2006 rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse Biochem Biophys Res Commun 343 1 190 197 16530728 1:CAS:528:DC%2BD28XivVOjsrw%3D 10.1016/j.bbrc.2006.02.141
125. L Manche SR Green, et al. 1992 Interactions between double-stranded RNA regulators and the protein kinase DAI Mol Cell Biol 12 11 5238 5248 1357546 1:CAS:528:DyaK38XmsVOls7w%3D
126. SE Martin NJ Caplen 2007 Applications of RNA interference in mammalian systems Annu Rev Genomics Hum Genet 8 81 108 17477824 1:CAS:528: DC%2BD2sXht1Wksr3J 10.1146/annurev.genom.8.080706.092424
127. LA Martinez I Naguibneva, et al. 2002 Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways Proc Natl Acad Sci USA 99 23 14849 14854 12403821 1:CAS:528:DC%2BD38Xpt1yrt7w%3D 10.1073/pnas.222406899 (Pubitemid 35334572)
128. MM Maxwell P Pasinelli, et al. 2004 RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells Proc Natl Acad Sci USA 101 9 3178 3183 14981234 1:CAS:528:DC%2BD2cXitlWhtb8%3D 10.1073/pnas.0308726100 (Pubitemid 38327754)
129. JL McBride RL Boudreau, et al. 2008 Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi Proc Natl Acad Sci USA 105 15 5868 5873 18398004 1:CAS:528:DC%2BD1cXltVyiur8%3D 10.1073/pnas.0801775105 (Pubitemid 351758464)
130. AP McCaffrey L Meuse, et al. 2003 A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice Hepatology 38 2 503 508 12883495 1:CAS:528:DC%2BD3sXmvFSmurk%3D 10.1053/jhep.2003.50330 (Pubitemid 36919872)
131. AP McCaffrey H Nakai, et al. 2003 Inhibition of hepatitis B virus in mice by RNA interference Nat Biotechnol 21 6 639 644 12740585 1:CAS:528: DC%2BD3sXktFSlu7w%3D 10.1038/nbt824 (Pubitemid 36638090)
132. TJ McCown 2005 Adeno-associated virus (AAV) vectors in the CNS Curr Gene Ther 5 3 333 338 15975010 1:CAS:528:DC%2BD2MXlsFemsr8%3D 10.2174/ 1566523054064995 (Pubitemid 40895017)
133. MT McManus PA Sharp 2002 Gene silencing in mammals by small interfering RNAs Nat Rev Genet 3 10 737 747 12360232 1:CAS:528:DC%2BD38XnsVGqs7k%3D 10.1038/nrg908
134. JO McNamara 2nd ER Andrechek, et al. 2006 Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat Biotechnol 24 8 1005 1015 16823371 1:CAS:528:DC%2BD28XnvVygt7o%3D 10.1038/nbt1223 (Pubitemid 44215395)
135. G Meister T Tuschl 2004 Mechanisms of gene silencing by double-stranded RNA Nature 431 7006 343 349 15372041 1:CAS:528:DC%2BD2cXnsFaiu7Y%3D 10.1038/nature02873 (Pubitemid 39265674)
136. VM Miller H Xia, et al. 2003 Allele-specific silencing of dominant disease genes Proc Natl Acad Sci USA 100 12 7195 7200 12782788 1:CAS:528:DC%2BD3sXkslOmsr8%3D 10.1073/pnas.1231012100 (Pubitemid 36706415)
137. VM Miller CM Gouvion, et al. 2004 Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles Nucleic Acids Res 32 2 661 668 14754988 1:CAS:528:DC%2BD2cXhtVKrs78%3D 10.1093/nar/gkh208 (Pubitemid 38263057)
138. JP Mounsey DJ Mistry, et al. 2000 Skeletal muscle sodium channel gating in mice deficient in myotonic dystrophy protein kinase Hum Mol Genet 9 15 2313 2320 11001935 1:CAS:528:DC%2BD3cXnt1yntb8%3D
139. A Muratovska MR Eccles 2004 Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells FEBS Lett 558 1-3 63 68 14759517 1:CAS:528:DC%2BD2cXpsV2gtg%3D%3D 10.1016/S0014-5793(03)01505-9 (Pubitemid 38167411)
140. F Noe A Frasca, et al. 2009 Neuropeptide Y overexpression using recombinant adeno-associated viral vectors Neurotherapeutics 6 2 300 306 19332323 1:CAS:528:DC%2BD1MXmtVOgs7g%3D 10.1016/j.nurt.2009.01.012
141. A Nykanen B Haley, et al. 2001 ATP requirements and small interfering RNA structure in the RNA interference pathway Cell 107 3 309 321 11701122 1:CAS:528:DC%2BD3MXosVKhsLc%3D 10.1016/S0092-8674(01)00547-5 (Pubitemid 33049975)
142. Y Ohnishi Y Tamura, et al. 2008 Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi PLoS One 3 5 e2248 18493311 10.1371/journal.pone.0002248 1:CAS:528:DC%2BD1cXnsVOgtrk%3D
143. T Ohrt J Mutze, et al. 2008 Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy reveal the cytoplasmic origination of loaded nuclear RISC in vivo in human cells Nucleic Acids Res 36 20 6439 6449 18842624 1:CAS:528:DC%2BD1cXhtl2hu73L 10.1093/nar/gkn693
144. SI Pai YY Lin, et al. 2006 Prospects of RNA interference therapy for cancer Gene Ther 13 6 464 477 16341059 1:CAS:528:DC%2BD28XitVGnu7w%3D 10.1038/sj.gt.3302694
145. HL Paulson 2000 Toward an understanding of polyglutamine neurodegeneration Brain Pathol 10 2 293 299 10764049 1:CAS:528: DC%2BD3cXivVyhurY%3D 10.1111/j.1750-3639.2000.tb00263.x (Pubitemid 30181098)
146. HL Paulson NM Bonini, et al. 2000 Polyglutamine disease and neuronal cell death Proc Natl Acad Sci USA 97 24 12957 12958 11058149 1:CAS:528: DC%2BD3cXosVKqtr0%3D 10.1073/pnas.210395797
147. R Pawliuk KA Westerman, et al. 2001 Correction of sickle cell disease in transgenic mouse models by gene therapy Science 294 5550 2368 2371 11743206 1:CAS:528:DC%2BD3MXptFGru7Y%3D 10.1126/science.1065806 (Pubitemid 33140563)
148. Y Pei T Tuschl 2006 On the art of identifying effective and specific siRNAs Nat Methods 3 9 670 676 16929310 1:CAS:528:DC%2BD28XosVOns70%3D 10.1038/nmeth911 (Pubitemid 44275732)
149. N Perrimon JQ Ni, et al. 2010 In vivo RNAi: today and tomorrow Cold Spring Harb Perspect Biol 2 8 a003640 20534712 10.1101/cshperspect.a003640 1:CAS:528:DC%2BC3cXhtlSitL3P
150. I Petrus M Chuah, et al. 2010 Gene therapy strategies for hemophilia: benefits versus risks J Gene Med 12 10 797 809 20848668 1:CAS:528: DC%2BC3cXhs1WltL3F 10.1002/jgm.1500
151. A Pfeifer S Eigenbrod, et al. 2006 Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice J Clin Invest 116 12 3204 3210 17143329 1:CAS:528:DC%2BD28XhtlWgsbjF 10.1172/JCI29236 (Pubitemid 44878634)
152. MH Polymeropoulos C Lavedan, et al. 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 5321 2045 2047 9197268 1:CAS:528:DyaK2sXkt1altr4%3D 10.1126/science.276.5321.2045 (Pubitemid 27443610)
153. K Quon PD Kassner 2009 RNA interference screening for the discovery of oncology targets Expert Opin Ther Targets 13 9 1027 1035 19650760 1:CAS:528:DC%2BD1MXpsFaltL0%3D 10.1517/14728220903179338
154. GS Ralph PA Radcliffe, et al. 2005 Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model Nat Med 11 4 429 433 15768029 1:CAS:528:DC%2BD2MXivFCgsro%3D 10.1038/nm1205 (Pubitemid 40562334)
155. C Raoul T Abbas-Terki, et al. 2005 Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS Nat Med 11 4 423 428 15768028 1:CAS:528:DC%2BD2MXivFCgsrg%3D 10.1038/nm1207 (Pubitemid 40562333)
156. C Raoul SD Barker, et al. 2006 Viral-based modelling and correction of neurodegenerative diseases by RNA interference Gene Ther 13 6 487 495 16319945 1:CAS:528:DC%2BD28XitVGnu78%3D 10.1038/sj.gt.3302690
157. S Reddy DB Smith, et al. 1996 Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy Nat Genet 13 3 325 335 8673132 1:CAS:528:DyaK28XktVegt78%3D 10.1038/ng0796-325 (Pubitemid 26230499)
158. BJ Reinhart FJ Slack, et al. 2000 The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans Nature 403 6772 901 906 10706289 1:CAS:528:DC%2BD3cXhs1Ors74%3D 10.1038/35002607 (Pubitemid 30130993)
159. V Riban HL Fitzsimons, et al. 2009 Gene therapy in epilepsy Epilepsia 50 1 24 32 18717707 1:CAS:528:DC%2BD1MXitVWnsrs%3D 10.1111/j.1528-1167.2008.01743.x
160. GB Robb TM Rana 2007 RNA helicase A interacts with RISC in human cells and functions in RISC loading Mol Cell 26 4 523 537 17531811 1:CAS:528:DC%2BD2sXmsVWksLc%3D 10.1016/j.molcel.2007.04.016 (Pubitemid 46765183)
161. GB Robb KM Brown, et al. 2005 Specific and potent RNAi in the nucleus of human cells Nat Struct Mol Biol 12 2 133 137 15643423 1:CAS:528: DC%2BD2MXhtV2qurs%3D 10.1038/nsmb886
162. A Rodriguez S Griffiths-Jones, et al. 2004 Identification of mammalian microRNA host genes and transcription units Genome Res 14 10A 1902 1910 15364901 1:CAS:528:DC%2BD2cXotl2hu7w%3D 10.1101/gr.2722704 (Pubitemid 39386503)
163. E Rodriguez-Lebron HL Paulson 2006 Allele-specific RNA interference for neurological disease Gene Ther 13 6 576 581 16355113 1:CAS:528: DC%2BD28XitVGnu70%3D 10.1038/sj.gt.3302702
164. E Rodriguez-Lebron EM Denovan-Wright, et al. 2005 Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice Mol Ther 12 4 618 633 16019264 1:CAS:528:DC%2BD2MXhtVWgsbzL 10.1016/j.ymthe.2005.05.006 (Pubitemid 41350143)
165. E Rodriguez-Lebron CM Gouvion, et al. 2009 Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease Mol Ther 17 9 1563 1573 19532137 1:CAS:528:DC%2BD1MXntlGnsb4%3D 10.1038/mt.2009.123
166. DW Sah 2006 Therapeutic potential of RNA interference for neurological disorders Life Sci 79 19 1773 1780 16815477 1:CAS:528:DC%2BD28XhtVajsLfN 10.1016/j.lfs.2006.06.011 (Pubitemid 44441450)
167. S Samakoglu L Lisowski, et al. 2006 A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference Nat Biotechnol 24 1 89 94 16378095 1:CAS:528:DC%2BD28XisVGksQ%3D%3D 10.1038/nbt1176 (Pubitemid 43083171)
168. MK Sapru JW Yates, et al. 2006 Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi Exp Neurol 198 2 382 390 16455076 1:CAS:528:DC%2BD28Xjs1ajtL8%3D 10.1016/j.expneurol.2005.12.024
169. S Saxena ZO Jonsson, et al. 2003 Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells J Biol Chem 278 45 44312 44319 12952966 1:CAS:528:DC%2BD3sXoslWmtLY%3D 10.1074/jbc.M307089200 (Pubitemid 37377177)
170. M Scherr K Battmer, et al. 2003 Specific inhibition of bcr-abl gene expression by small interfering RNA Blood 101 4 1566 1569 12393533 1:CAS:528:DC%2BD3sXht1ansrs%3D 10.1182/blood-2002-06-1685 (Pubitemid 36182535)
171. J Scholefield LJ Greenberg, et al. 2009 Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype PLoS One 4 9 e7232 19789634 10.1371/journal.pone.0007232 1:CAS:528:DC%2BD1MXht1altLvI
172. DS Schwarz G Hutvagner, et al. 2003 Asymmetry in the assembly of the RNAi enzyme complex Cell 115 2 199 208 14567917 1:CAS:528:DC%2BD3sXosFCqsLo%3D 10.1016/S0092-8674(03)00759-1 (Pubitemid 37329583)
173. DS Schwarz H Ding, et al. 2006 Designing siRNA that distinguish between genes that differ by a single nucleotide PLoS Genet 2 9 e140 16965178 10.1371/journal.pgen.0020140
174. A Sengupta D Banerjee, et al. 2006 Gene therapy for BCR-ABL + human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector J Gene Med 8 10 1251 1261 16952195 1:CAS:528:DC%2BD28Xht1OksrrL 10.1002/jgm.959 (Pubitemid 44660524)
175. AA Seyhan TE Ryan 2010 RNAi screening for the discovery of novel modulators of human disease Curr Pharm Biotechnol 11 735 756 20420566 1:CAS:528:DC%2BC3cXhsVCisbbE 10.2174/138920110792927766
176. AA Seyhan AV Vlassov, et al. 2005 Complete, gene-specific siRNA libraries: production and expression in mammalian cells RNA 11 5 837 846 15840823 1:CAS:528:DC%2BD2MXktFejtr4%3D 10.1261/rna.7285805 (Pubitemid 40594348)
177. AA Seyhan BN Alizadeh, et al. 2007 RNA interference-mediated inhibition of Semliki Forest virus replication in mammalian cells Oligonucleotides 17 4 473 484 18095875 1:CAS:528:DC%2BD1cXhtFymtA%3D%3D 10.1089/oli.2007.0079
178. Singer O, Marr RA et al (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8(10):1343-1349 (Pubitemid 41630422)
179. AB Singleton M Farrer, et al. 2003 Alpha-synuclein locus triplication causes Parkinson's disease Science 302 5646 841 14593171 1:CAS:528: DC%2BD3sXoslehsbc%3D 10.1126/science.1090278 (Pubitemid 37339619)
180. CA Sledz BR Williams 2004 RNA interference and double-stranded-RNA- activated pathways Biochem Soc Trans 32 Pt 6 952 956 15506933 1:CAS:528:DC%2BD2cXptVSltL8%3D (Pubitemid 39655513)
181. CA Sledz M Holko, et al. 2003 Activation of the interferon system by short-interfering RNAs Nat Cell Biol 5 9 834 839 12942087 1:CAS:528: DC%2BD3sXmvVWlur4%3D 10.1038/ncb1038 (Pubitemid 37087172)
182. E Song P Zhu, et al. 2005 Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat Biotechnol 23 6 709 717 15908939 1:CAS:528:DC%2BD2MXkvVShs70%3D 10.1038/nbt1101 (Pubitemid 41716361)
183. J Soutschek A Akinc, et al. 2004 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs Nature 432 7014 173 178 15538359 1:CAS:528:DC%2BD2cXpsF2gt7k%3D 10.1038/nature03121 (Pubitemid 39545841)
184. MG Spillantini ML Schmidt, et al. 1997 Alpha-synuclein in Lewy bodies Nature 388 6645 839 840 9278044 1:CAS:528:DyaK2sXlslWru7o%3D 10.1038/42166 (Pubitemid 27377048)
185. H Sumimoto K Hirata, et al. 2006 Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi Int J Cancer 118 2 472 476 16052531 1:CAS:528: DC%2BD2MXhtlWqsL%2FL 10.1002/ijc.21286 (Pubitemid 41779089)
186. HS Sun MF Jackson, et al. 2009 Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia Nat Neurosci 12 10 1300 1307 19734892 1:CAS:528:DC%2BD1MXhtV2gsb3J 10.1038/nn.2395
187. F Takeshita T Ochiya 2006 Therapeutic potential of RNA interference against cancer Cancer Sci 97 8 689 696 16863503 1:CAS:528:DC%2BD28Xot1CntbY%3D 10.1111/j.1349-7006.2006.00234.x (Pubitemid 43983779)
188. K Tanemura M Murayama, et al. 2002 Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau J Neurosci 22 1 133 141 11756496 1:CAS:528:DC%2BD38XislWlug%3D%3D (Pubitemid 34033491)
189. R Taulli C Scuoppo, et al. 2006 Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma Cancer Res 66 9 4742 4749 16651427 1:CAS:528:DC%2BD28XjvF2ktr0%3D 10.1158/0008-5472.CAN-05-4292
190. R Tawil SM Van Der Maarel 2006 Facioscapulohumeral muscular dystrophy Muscle Nerve 34 1 1 15 16508966 1:CAS:528:DC%2BD28XnsVCqsr0%3D 10.1002/mus.20522
191. R Tawil S van der Maarel, et al. 2010 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy Neuromuscul Disord 20 7 471 475 20554202 10.1016/j.nmd.2010.04.007
192. AH Ting KE Schuebel, et al. 2005 Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation Nat Genet 37 8 906 910 16025112 1:CAS:528:DC%2BD2MXmsFKlsLY%3D 10.1038/ng1611 (Pubitemid 41077120)
193. AK Vaishnaw J Gollob, et al. 2010 A status report on RNAi therapeutics Silence 1 1 14 20615220 10.1186/1758-907X-1-14 1:CAS:528:DC%2BC3cXovFGrtLk%3D
194. JC Venter MD Adams, et al. 2001 The sequence of the human genome Science 291 5507 1304 1351 11181995 1:CAS:528:DC%2BD3MXhtlSgsbo%3D 10.1126/science. 1058040 (Pubitemid 32173090)
195. L Venturini M Eder, et al. 2006 RNA-mediated gene silencing in hematopoietic cells J Biomed Biotechnol 2006 4 87340 17057372
196. AV Vlassov B Korba, et al. 2007 shRNAs targeting hepatitis C: effects of sequence and structural features, and comparison with siRNA Oligonucleotides 17 2 223 236 17638526 1:CAS:528:DC%2BD2sXnsl2gu7c%3D 10.1089/oli.2006.0069 (Pubitemid 47124419)
197. Wallace, LM, Garwick SE et al (2010) RNAi therapy for dominant muscular dystrophies and other myopathies. Muscle Gene Therapy 99-115. doi: 10.1007/978-1-4419-1207-7-7
198. YL Wang W Liu, et al. 2005 Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA Neurosci Res 53 3 241 249 16095740 1:CAS:528:DC%2BD2MXhtFektbzN 10.1016/j.neures.2005.06.021 (Pubitemid 41463777)
199. L Weinmann J Hock, et al. 2009 Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs Cell 136 3 496 507 19167051 1:CAS:528:DC%2BD1MXltFSnsrk%3D 10.1016/j.cell.2008.12.023
200. MD White M Farmer, et al. 2008 Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease Proc Natl Acad Sci USA 105 29 10238 10243 18632556 1:CAS:528:DC%2BD1cXpt1Sju74%3D 10.1073/pnas.0802759105
201. B Wightman I Ha, et al. 1993 Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans Cell 75 5 855 862 8252622 1:CAS:528:DyaK2cXislyisA%3D%3D 10.1016/0092-8674(93)90530-4 (Pubitemid 24014543)
202. M Wilda U Fuchs, et al. 2002 Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi) Oncogene 21 37 5716 5724 12173041 1:CAS:528:DC%2BD38XntVait70%3D 10.1038/sj.onc.1205653
203. L Wohlbold H van der Kuip, et al. 2003 Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) Blood 102 6 2236 2239 12750174 1:CAS:528:DC%2BD3sXntlKrsLo%3D 10.1182/blood-2002-12-3899 (Pubitemid 37122404)
204. JA Wolff V Budker 2005 The mechanism of naked DNA uptake and expression Adv Genet 54 3 20 16096005 1:CAS:528:DC%2BD1cXivFWrtrc%3D
205. H Xia Q Mao, et al. 2004 RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia Nat Med 10 8 816 820 15235598 1:CAS:528:DC%2BD2cXmtFWrtro%3D 10.1038/nm1076 (Pubitemid 39070854)
206. A Yamamoto JJ Lucas, et al. 2000 Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 1 57 66 10778856 1:CAS:528:DC%2BD3cXisVaitbk%3D 10.1016/S0092-8674(00)80623-6
207. M Yang J Mattes 2008 Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs Pharmacol Ther 117 1 94 104 17928059 1:CAS:528:DC%2BD2sXhsVSmtL3K 10.1016/j.pharmthera.2007.08.004 (Pubitemid 350199690)
208. R Yi Y Qin, et al. 2003 Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs Genes Dev 17 24 3011 3016 14681208 1:CAS:528:DC%2BD2cXhs1Shsg%3D%3D 10.1101/gad.1158803 (Pubitemid 38040764)
209. PD Zamore B Haley 2005 Ribo-gnome: the big world of small RNAs Science 309 5740 1519 1524 16141061 1:CAS:528:DC%2BD2MXpsFWisrg%3D 10.1126/science. 1111444 (Pubitemid 41266468)
210. PD Zamore T Tuschl, et al. 2000 RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals Cell 101 1 25 33 10778853 1:CAS:528:DC%2BD3cXisVaitbo%3D 10.1016/S0092-8674(00)80620-0
211. Y Zhang YF Zhang, et al. 2004 Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer Clin Cancer Res 10 11 3667 3677 15173073 1:CAS:528:DC%2BD2cXksVKnsbg%3D 10.1158/1078-0432.CCR-03-0740 (Pubitemid 38697600)
212. B Zhang Q Wang, et al. 2007 MicroRNAs and their regulatory roles in animals and plants J Cell Physiol 210 2 279 289 17096367 1:CAS:528: DC%2BD28XhtlGqsbjF 10.1002/jcp.20869 (Pubitemid 44956872)
213. HF Zhao D L'Abbe, et al. 2005 High-throughput screening of effective siRNAs from RNAi libraries delivered via bacterial invasion Nat Methods 2 12 967 973 16299483 1:CAS:528:DC%2BD2MXht1aksr3I 10.1038/nmeth812 (Pubitemid 43108734)
214. J Zhou H Li, et al. 2008 Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy Mol Ther 16 8 1481 1489 18461053 1:CAS:528:DC%2BD1cXptVWrs70%3D 10.1038/mt.2008.92
215. H Zhu W Guo, et al. 2005 Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA Cancer Biol Ther 4 4 393 397 15846108 1:CAS:528:DC%2BD28Xitl2rsbc%3D 10.4161/cbt.4.4.1616
216. TS Zimmermann AC Lee, et al. 2006 RNAi-mediated gene silencing in non-human primates Nature 441 7089 111 114 16565705 1:CAS:528: DC%2BD28XktVGlt7w%3D 10.1038/nature04688
217. HY Zoghbi HT Orr 2000 Glutamine repeats and neurodegeneration Annu Rev Neurosci 23 217 247 10845064 1:CAS:528:DC%2BD3cXjs1Gmsrw%3D 10.1146/annurev. neuro.23.1.217 (Pubitemid 30350043)